HOME >> BIOLOGY >> NEWS
Trial shows which brain cancer patients benefit from temozolomide

Geneva, Switzerland: An international team of scientists and cancer specialists has identified which patients with the deadly form of brain tumours called glioblastomas are likely to live longer if they are treated with temozolomide, and which patients are likely to get only marginal, if any, benefit.

The genetic predictive test on tumour biopsies to identify who will benefit from the drug could be carried out fairly easily in any genetics laboratory and takes only two to three days, although the availability and quality of the tissue is an important issue. If implemented widely it would mean that temozolomide would become a targeted treatment.

Dr. Monika Hegi told the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva today (Wednesday 29 September) that the key to predicting which patients will gain from temozolomide was a gene called O-6-methylguanine-DNA methyltransferase (MGMT) which is involved in DNA repair and its respective methylation status in the patient's tumour.

Methylation is one of the ways that cells control which genetic information they will use. If the MGMT promoter is methylated, the MGMT gene is silenced and this means that no MGMT repair enzyme will be produced, thus preventing correction of faults in the DNA.

Dr. Hegi, head of the laboratory of tumour biology and genetics at the Department of Neurosurgery, University Hospital of Lausanne, Switzerland, said that of a total of 573 patients, biopsies from 206 glioblastoma patients had been tested successfully so far in a seven-country trial organised by the EORTC and National Cancer Institute of Canada Clinical Trials Group (NCIC). 45% had a methylated MGMT promoter, meaning that the MGMT gene was silent and their DNA repair system was impaired.

In this tested group 106 of the patients have been treated with radiotherapy and temozolomide. There was a 46% survival rate at two years for the 46 patients in the group who had a
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
29-Sep-2004


Page: 1 2 3

Related biology news :

1. Trial found no impact of Malarone(TM) on performance and alertness tasks
2. Trial drugs for Huntingtons disease inconclusive in slowing disease
3. National Institute on Drug Abuse launches National Drug Addiction Treatment Clinical Trials Network
4. Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure
5. Gene Therapy Trial Approved For Rare Anemia
6. Severe Pain Following Shingles Safely Relieved In Clinical Trial Of Anti-Convulsant Drug Gabapentin
7. Cardiac Clinical Trial Studies Use of Antibiotic In Preventing Heart Attack
8. Clinical Trials Show That Bone Marrow Transplant And Vitamin A Derivative Both Improve Survival From Neuroblastoma
9. Novel Drug Trial To Treat Advanced Prostate Cancer Enrolling Patients At UCSF/Mount Zion Cancer Center
10. Targeted Genetics, M.D. Anderson Cancer Center And University Of Pittsburgh Report Phase I Clinical Trial Results Of Gene Therapy Treatment For Cancer
11. Experimental Trial Combines DNA Vaccine With Triple-Drug Therapy To Stop HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):
(Date:6/26/2017)... ... 26, 2017 , ... Third Wave Bioactives, LLC announces the addition of Brett ... new business development and ensuring quality customer experience. , Brett brings to ... in technical, marketing and sales roles. “Brett’s background working with customers and eye for ...
(Date:6/23/2017)... ... June 23, 2017 , ... RURO, Inc., a leading LIMS, ... its rapidly growing Laboratory Information System. , LimitLIS® version 3 is includes new ... provide more customization options. Each of these has been “under the microscope” in ...
(Date:6/22/2017)... ... June 21, 2017 , ... Beaker, the ... talent in the life sciences industry, today announces a strategic partnership with Alcami ... takes full advantage of Beaker’s expertise in executive recruitment solutions, providing Alcami with ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... leaders in designating infertility as a disease, bringing new hope for prospective parents ... their 2017 annual meeting to back the World Health Organization’s designation in hopes ...
Breaking Biology Technology:
Cached News: